{"entity":{"id":"nct06863272","kind":"trial","name":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)","aka":["IDeate-Prostate02"],"tldr":"A phase 1/2 trial of Docetaxel, Ifinatamab deruxtecan, Opevesostat and Enzalutamide in prostate cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) is a phase 1/2 interventional study registered as NCT06863272 by Merck Sharp & Dohme LLC, with 360 participants planned, started 2025-07-03 and due to reach its primary completion in 2031-04-01. Interventions recorded: Docetaxel, Ifinatamab Deruxtecan, Opevesostat, Abiraterone, Enzalutamide and Rescue Medication.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06863272","url":"https://clinicaltrials.gov/study/NCT06863272"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-mcrpc"],"sections":[],"technologies":["adc"],"targets":[],"drugs":["docetaxel","ifinatamab-deruxtecan","opevesostat","enzalutamide"],"companies":["merck","daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06863272","phase":"1/2","setting":"MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06863272","source":"https://clinicaltrials.gov/study/NCT06863272","fetchedAt":"2026-10-07T16:55:12.940Z","studySha256":"b11bf92e9f7e950392f0364a6a1780477c0901476aa7ccbc325446e42fab8b89","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":360,"enrolmentType":"ESTIMATED","siteCount":82,"recruitingSiteCount":80,"countries":["Argentina","Australia","Brazil","Canada","Chile","France","Germany","Ireland","Israel","Italy","Netherlands","New Zealand","Poland","South Korea","Spain","Taiwan","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-07-03","startedType":"actual","enrolled":360,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06863272/","neighbours":{"cancer":[{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"drug":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"ifinatamab-deruxtecan","kind":"drug","name":"Ifinatamab deruxtecan","route":"/drugs/ifinatamab-deruxtecan/"},{"id":"opevesostat","kind":"drug","name":"Opevesostat","route":"/drugs/opevesostat/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}